AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05540951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC
Description: VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
Study NCT05540951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Plus Chemotherapy
Description: Bevacizumab Plus Doublet or Triplet Chemotherapy
Study NCT02206100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation
Study NCT02206100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Study NCT05356871 — intervention group
Intervention type: OTHER
Intervention: VO2max validity and reliability assesment
Description: Reliability assessment of VO2max determination with three repeated measures for two methods.
Study NCT02812524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral Ipilimumab
Description: Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
Study NCT01366924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids
Description: 10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
Study NCT02130375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the IncontiLaseTM procedure
Description: Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
Study NCT04182581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA/CD19 Dual-Target CAR-T
Description: BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
Study NCT02315235 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline is injected in one leg of patient.
Study NCT02315235 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem-cell
Description: Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient.
Study NCT04224766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block with 5ml bupivicaine 0.5%
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
Study NCT04224766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costoclavicular Block 10ml bupivicaine 0.5%
Description: transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
Study NCT04224766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
Study NCT04520945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chondrogen
Description: Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
Study NCT04520945 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consist of saline and hyaluronic acid
Study NCT01366924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acids
Description: 10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
Study NCT01366924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance exercise
Description: 60 minute endurance exercise session
Study NCT00212446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Intervention (EI)
Description: Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
Study NCT01038076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedCHEC Tablet Computer & Adherence Care
Description: Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
Study NCT02452606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo®
Description: * Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective.
Study NCT04515147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 6 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT04515147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12 μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT04515147 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT04515147 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT04515147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV 12μg
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT02555579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Protein Counting and Free Fruits and Vegetables
Description: Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
Study NCT02810873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Undergo PEM Positron Emission Mammography scan
Study NCT02810873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET Positron Emission Tomography scan
Study NCT02810873 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Study NCT02810873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Study NCT04482764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
Study NCT03134248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dailies Aquacomfort Plus Toric
Description: daily disposable contact lens
Study NCT03134248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-Day Acuvue Moist for Astigmatism
Description: daily disposable contact lens
Study NCT03134248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyDay Toric
Description: daily disposable contact lens
Study NCT00402077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, three times a day, 120mcg
Study NCT00402077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: oral tablet, once a day, 10mg
Study NCT00402077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: oral tablet, once a day, 37.5mg
Study NCT00402077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, three times a day
Study NCT03606343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Academic Skills to Kids
Description: Group treatment
Study NCT01910493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
Study NCT01910493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
Study NCT00991393 — intervention group
Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study NCT03683264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound diagnosis of avulsion of the levator ani muscle
Description: In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
Study NCT03226782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short intervention protocol
Description: Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
Study NCT03226782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long intervention protocol
Description: This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
Study NCT04794595 — intervention group
Intervention type: PROCEDURE
Intervention: CBP
Description: continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
Study NCT01612988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOMP
Description: Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3
Study NCT01795404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Study NCT01932515 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: A revised screening instrument for use in Deaf children
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aprepitant
Description: aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: ondansetron
Description: Ondansetron 8 mg capsule Three day treatment period.
Study NCT04084353 — intervention group
Intervention type: OTHER
Intervention: Intrapartum fetal monitoring training and quality improvement project
Description: Intrapartum fetal monitoring training
Study NCT00799617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel® (testosterone gel)
Description: Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
Study NCT00799617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Testosterone levels will be measured at regular intervals.
Study NCT03365284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Kneebrace with a smart phone app
Description: Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
Study NCT03365284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: regular rehabilitation procedure
Description: regular rehabilitation procedure, especially muscle strengthening exercises
Study NCT03545607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: single intravenous infusion 18-36 hours after stroke
Study NCT03545607 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intravenous infusion 18-36 hours after stroke
Study NCT03837795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment
Description: A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
Study NCT03413332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Talkcare
Description: Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
Study NCT03413332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
Study NCT02143570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
Study NCT02143570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
Study NCT02143570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
Study NCT02227524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No device
Description: Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
Study NCT02227524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-point cane (SPC)
Description: Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
Study NCT02227524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Four-point cane (FPC)
Description: Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
Study NCT02227524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trekking pole (TP).
Description: Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
Study NCT00676442 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PN400
Description: naproxen/esomeprazole
Study NCT03955042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
Study NCT01513252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gröber and Buschke test
Description: spontaneous delayed recall score after a 5 years follow-up
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: dexamethasone
Description: dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: fosaprepitant dimeglumine
Description: fosaprepitant dimeglumine 115 mg
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator; Placebo (unspecified)
Description: dexamethasone 12mg Pbo tablets.
Study NCT03940378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Hydrochloride
Description: Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
Study NCT03940378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
Study NCT00337727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator; Placebo (unspecified)
Description: Aprepitant 80 mg \& 125 mg Pbo capsules.
Study NCT03444909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiotocograph
Description: Monitoring of 20 min with the cardiotocograph
Study NCT03632291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)
Study NCT03061539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Ipilimumab
Description: Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent
Study NCT01516879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection once a month
Study NCT01516879 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month